儿童肾移植受者避免激素方案后的移植物存活:倾向评分匹配研究
该研究基于2004-2014年器官获取与移植网络数据库,纳入接受他克莫司和霉酚酸酯免疫抑制的儿童肾移植受者,通过倾向评分匹配比较1624例避免激素与1624例含激素方案的移植物存活。避免激素组5年移植物存活率轻度改善(84.8% vs 81.2%,P=0.03),获益主要见于移植后前2年(HR=0.62,95%CI 0.45-0.86),2-10年无显著差异(HR=0.93,95%CI 0.75-1.15)。在免疫学风险亚组中,避免激素未显著增加移植物失败风险。
要点
- 儿童肾移植避免激素方案5年移植物存活率轻度改善。
- 获益主要发生在移植后前2年,2年后无显著差异。
- 具有免疫学风险因素的儿童可安全采用避免激素方案。
核心结论
- 在接受他克莫司和霉酚酸酯免疫抑制的儿童肾移植受者中,避免激素方案可安全用于具有免疫学风险因素的儿童。
研究设计与样本
- 回顾性队列研究,使用2004-2014年器官获取与移植网络数据库数据,纳入接受他克莫司和霉酚酸酯的儿童肾移植受者。
- 采用倾向评分匹配比较1624例避免激素与1624例含激素方案的受者。
- 在匹配队列中使用Cox比例风险回归评估免疫学风险分层中避免激素对移植物失败的影响。
主要发现
- 避免激素组5年移植物存活率为84.8%,含激素组为81.2%(P=0.03)。
- 移植后前2年,避免激素组同种异体移植物失败的风险比(HR)为0.62(95%CI 0.45-0.86)。
- 移植后2-10年,避免激素组同种异体移植物失败的HR为0.93(95%CI 0.75-1.15)。
- 在2-10年期间,免疫学风险亚组(再次肾移植、非裔美国人、致敏受者、 deceased donor、完全HLA错配、移植前肾小球疾病)的HR(95%CI)与1无显著差异。
临床怎么用
- 对于接受他克莫司和霉酚酸酯的儿童肾移植受者,可考虑避免激素方案,包括具有免疫学风险因素者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Steroid-avoidance protocols have gained popularity in pediatric kidney transplant recipients at low immunologic risk. The long-term safety of steroid avoidance in children with immunologic risk factors remains unknown. METHODS: Pediatric kidney transplant recipients from 2004 to 2014 in the Organ Procurement and Transplantation Network database who received tacrolimus and mycophenolate immunosuppression were investigated. Propensity score matching was used to compare graft survival in 1624 children who received steroid avoidance with 1624 children who received steroid-based immunosuppression. The effect of steroid avoidance on graft failure among immunologic risk strata was estimated using Cox proportional hazards regression in this propensity score-matched cohort. RESULTS: It was observed that 5-year graft survival was mildly improved in children receiving steroid avoidance (84.8% versus 81.2%, P = 0.03). This improvement in graft survival occurred in the first 2 years following transplant, when the hazard ratio (HR) for allograft failure in children receiving steroid avoidance was 0.62 [95% confidence interval (CI) 0.45-0.86]. In contrast, steroid avoidance was not associated with improved allograft survival during Years 2-10 following transplant (HR = 0.93; 95% CI 0.75-1.15). During this time period, HRs (95% CIs) for allograft failure within immunologic risk strata were not significantly different from the null value of 1: repeat kidney transplants, 1.84 (0.84-4.05); African-Americans, 1.02 (0.67-1.56); sensitized recipients, 1.24 (0.63-2.43); recipients of deceased donor kidneys, 1.02 (0.79-1.32); recipients of completely human leukocyte antigen-mismatched kidneys, 0.80 (0.47-1.37); and recipients with pretransplant glomerular disease, 0.94 (0.71-1.23). CONCLUSIONS: In pediatric kidney transplant recipients receiving tacrolimus- and mycophenolate-based immunosuppression, steroid avoidance can be safely practiced in children with immunologic risk factors.
引用
- Nehus EJ, Liu C, Lu B, et al. Graft survival of pediatric kidney transplant recipients selected for de novo steroid avoidance-a propensity score-matched study. Nephrol Dial Transplant. 2017. PMID: 28810723. doi:10.1093/ndt/gfx193
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。